| Umberto Coletta, MD | |
|
425 Jack Martin Blvd, Ocean Med Ctr Dept Of Pathology, Brick, NJ 08724 | |
| (732) 840-3237 | |
| Not Available |
| Full Name | Umberto Coletta |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 44 Years |
| Location | 425 Jack Martin Blvd, Brick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437218641 | NPI | - | NPPES |
| 8045208 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 25MAO4645500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ocean Medical Center | Brick, NJ | Hospital |
| Southern Ocean Medical Center | Manahawkin, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Meridian Laboratory Physicians, Pa | 5193707032 | 16 |
News Archive
Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 7 days ago
| Entity Name | Shore Health Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902944416 PECOS PAC ID: 0547254047 Enrollment ID: O20040408000832 |
News Archive
Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 7 days ago
| Entity Name | Meridian Laboratory Physicians, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104903723 PECOS PAC ID: 5193707032 Enrollment ID: O20040603001035 |
News Archive
Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 7 days ago
| Entity Name | Advanced Digestive Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962423053 PECOS PAC ID: 9436167665 Enrollment ID: O20060330000249 |
News Archive
Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 7 days ago
| Entity Name | Optum Medical Care Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578665048 PECOS PAC ID: 3072650290 Enrollment ID: O20091021000129 |
News Archive
Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Umberto Coletta, MD 28 Heyward Hills Drive, Holmdel, NJ 07733 Ph: (732) 840-3237 | Umberto Coletta, MD 425 Jack Martin Blvd, Ocean Med Ctr Dept Of Pathology, Brick, NJ 08724 Ph: (732) 840-3237 |
News Archive
Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
According to U.S. government researchers, a new nasal vaccine against influenza, which helps patients avoid the needle, has caused no unexpected side-effects.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Interlace Medical, Inc., today announced that it has initiated a multi-center clinical trial of the MyoSure Hysteroscopic Tissue Removal System. The purpose of this study is to demonstrate that women experience minimal to no pain or discomfort during a MyoSure procedure, when given a mild oral sedative together with a local anesthetic injected into the cervix.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 7 days ago
Henry Schneider, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 425 Jack Martin Blvd, Dept Pathology, Brick, NJ 08724 Phone: 732-840-3217 Fax: 732-458-3851 | |
Chitra Lahoti, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-3352 Fax: 732-458-3851 | |
Dr. Martin Saul Krumerman, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 525 Route 70, Brick, NJ 08723 Phone: 732-920-1772 Fax: 732-920-0679 | |
Anis Rangwala, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 425 Jack Martin Blvd, Dept Of Pathology Ocean Med Center, Brick, NJ 08724 Phone: 732-840-3218 Fax: 732-458-3851 |